Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900037 | 1.00 | NQO2 (0.43) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL29561955 | 1.00 | NQO2 (0.43) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL221006 | 1.00 | NQO2 (0.43) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL3143084 | 1.00 | NQO2 (0.43) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL28004385 | 1.00 | NQO2 (0.43) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL385259 | 0.98 | NQO2 (0.42) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL30626131 | 0.98 | NQO2 (0.42) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL29693806 | 0.98 | NQO2 (0.42) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL547432 | 0.98 | NQO2 (0.42) | NQO2MTNR1AMTNR1BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL29693778 | 0.98 | NQO2 (0.42) | NQO2MTNR1AMTNR1BCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198485-B2 | Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2012-06-12 | — | — | US | claimed |
| US-20120004463-A1 | RESOLUTION OF 4,5-DIMETHOXY-1-(METHYLAMINOMENTHYL)-BENZOCYCLOBUTANE | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-01-05 | — | — | US | claimed |
| EP-2097383-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | Cadila Healthcare Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2008065681-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-06-05 | — | — | WO | claimed |
| EP-3303297-B1 | NEW METHOD FOR THE PREPARATION OF HIGHLY PURE IVABRADINE BASE AND SALTS THEREOF | URQUIMA SA (ES) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| EP-3331862-A1 | A PROCESS FOR PREPARATION OF SOLID IVABRADINE HYDROCHLORIDE | Synthon BV (NL) | 2018-06-13 | — | — | EP | disclosed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| EP-3156399-A1 | POLYMORPHIC FORMS OF IVABRADINE HYDROCHLORIDE | Cadila Healthcare Limited (IN) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017021466-A1 | A PROCESS FOR PREPARATION OF SOLID IVABRADINE HYDROCHLORIDE | SYNTHON B.V. (NL) | 2017-02-09 | — | — | WO | disclosed |
| EP-2803659-B1 | Method for synthesising 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid | SERVIER LAB (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-9506095-B2 | Process for the enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid or esters thereof, and application in the synthesis of ivabradine and salts thereof | LES LABORATORIES SERVIER (FR) | 2016-11-29 | — | — | US | disclosed |
| WO-2009066041-A2 | DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009062377-A1 | RESOLUTION OF 4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)-BENZOCYCLOBUTANE | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2009-05-22 | — | — | WO | disclosed |
| EP-2036892-A1 | 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
| WO-2008065681-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-06-05 | — | — | WO | disclosed |
| EP-1345594-B1 | THERMOFORMABLE SOLID PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF IVABRADINE | SERVIER LAB (FR) | 2007-01-24 | — | — | EP | disclosed |
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| EP-0534859-A1 | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases | ADIR ET COMPAGNIE (FR) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004463-A1 | RESOLUTION OF 4,5-DIMETHOXY-1-(METHYLAMINOMENTHYL)-BENZOCYCLOBUTANE | DLAT, DLST, ADH1A | NQO2 2746/4885MTNR1A 2612/4885MTNR1B 2705/4885 |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | NQO2 1600/4885MTNR1A 60/4885MTNR1B 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.